Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients

Following an interim review of mortality data by an independent data monitoring committee (DMC), Apellis Pharmaceuticals Inc (NASDAQ: APLS) will not pursue additional development of APL-9 for the treatment of severe COVID-19.
DMC reviewed data from the Phase 1/2 study of APL-9 found no meaningful reduction in the overall mortality rate in APL-9 combined with the standard of care arm, compared to standard of care alone.
No safety signals were observed. No additional endpoints were analyzed as part of the interim review by the DMC.
Apellis plans to provide full results in a scientific forum following the completion of the full data analysis.
APL-9 is designed to control the complement cascade centrally at C3 and may potentially treat a range of diseases caused by excessive or uncontrolled activation of complement.
Price Action: APLS shares closed 0.3% higher at $45.65 on Thursday.

Momentum8.10

GrowthN/A

QualityN/A

Value46.38

Short

Medium

Long